Evidence map›Paper›PMID 37560396›Full record

ArticleAddiction & health2023

Promoter Methylation of Two

Majid Mahmoodi, Fatemeh Karami, Hamidreza Abdollahi, Navidreza Giahi, Kouros Divsalar, Amin Honarmand, Mohammad Hossein Modarressi

Abstract read
In one paragraph

Article in Addiction & health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Majid MahmoodiNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0003-3214-8168
Fatemeh KaramiNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-9590-754X
Hamidreza AbdollahiDepartment of Medical Genetics, Applied Biophotonics Research Center, Science and Research Branch, Islamic Azad University, Tehran, Iran.ORCID https://orcid.org/0000-0002-5285-023X
Navidreza GiahiAkhtar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-9654-5165
Kouros DivsalarNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-8810-3578
Amin HonarmandDepartment of Emergency Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0001-9755-9238
Mohammad Hossein ModarressiDepartment of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2763-1964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Opiate abuse has been critically increased in the world, especially in Iran. Owing to the association of opiate use with multiple human cancers and neurological disorders, seeking for genetic and epigenetic effects of opium can pave the way for early diagnosis of major health defects in addicted users. Accordingly, the present study aimed to determine the methylation status of the promoter of two genes, which are actively involved in neurodevelopment and cancer evolution. Methods: DNA was isolated from peripheral blood of 28 opium abusers and 19 healthy controls and then subjected to sonication. Sonicated DNAs undergone methylated DNA immunoprecipitation-real time polymerase chain reaction (MeDIP-Real Time PCR) using specific primer pairs designed for Findings: Conclusion: Hypermethylation of

Indexed as

HOXA9MeDIP-real time PCRNISCHOpiumPromoter methylation

Identifiers

PMID37560396
PMCPMC10408764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.